Skip to main content

Table 7 Sensitivity analysis in a health economic model of a cohort of IMSS T1D adult patients to determine the ICER of CSII therapy compared to MDI therapy

From: Cost-effectiveness of the use of the continuous subcutaneous insulin infusion pump versus daily multiple injections in type 1 diabetes adult patients at the Mexican Institute of Social Security

  ICER
(MXN/QALY)
ICER
(USD/QALY)
CSII MDI
Total costs
(MXN)
Total costs
(USD)
QALY Total costs
(MXN)
Total costs
(USD)
QALY
Base case (direct costs) 478,020 25,993 1,404,173 76,355 7.052 1,110,573 60,390 6.438
Secondary case (direct and indirect costs) 369,593 20,097 1,832,057 99,622 7.052 1,605,053 87,279 6.438
50% reduction in HbA1c benefit (− 0.6%) 903,984 49,156 1,404,910 76,395 6.764 1,110,573 60,390 6.438
Disc rate: 3% costs + 0% benefits 216,246 11,759 1,831,524 99,593 13.266 1,441,026 78,359 11.46
Disc rate: 7% costs + 7% benefits 533,083 28,988 1,123,780 61,108 5.836 890,663 48,432 5.399
Subgroup HbA1c ≤ 9% 1,334,460 72,564 1,403,917 76,341 7.436 1,056,824 57,467 7.176
Subgroup HbA1c > 9% 262,237 14,260 1,360,833 73,999 6.633 1,069,567 58,160 5.522
Subgroup ≤ 10 years 537,432 29,224 1,271,697 69,152 7.993 928,010 50,463 7.354
Subgroup > 10 years 1,376,224 74,835 1,022,134 55,581 3.249 814,737 44,303 3.098